Adamis and La Jolla Pharmaceutical to merge
This article was originally published in Scrip
Adamis Pharmaceuticals has entered a merger agreement to acquire fellow US firm La Jolla Pharmaceutical Company. The deal has been approved by both boards of directors and, subject to closing conditions including shareholder approval, is expected to close in the first quarter of next year.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.